| PE | Sector PE | P/B | Div. Yield | ROE |
|---|---|---|---|---|
| 11.27 | 27.88 | 0.98 | -- | 9.43% |
Gennex Laboratories’ 51%-owned subsidiary, Deccan Remedies, received Andhra Pradesh drug-control approval to manufacture and sell six additional products for domestic and export markets. The products included caffeine, duloxetine hydrochloride, mebeverine hydrochloride, phenylephrine hydrochloride, trimebutine maleate and oxyclozanide, under licences valid until 28 May 2028. Deccan Remedies also received a three-year test licence for ranolazine, cinnarizine, sacubitril and triclabendazole, which was restricted to examination, testing or analysis rather than commercial sale. The subsidiary generated revenue of ₹52.99 crore and PAT of ₹4.85 crore in FY26, while Gennex’s consolidated FY26 operating revenue was about ₹173 crore.
Powered by Tijori
Gennex Laboratories’ 51%-owned subsidiary, Deccan Remedies, received Andhra Pradesh drug-control approval to manufacture and sell six additional products for domestic and export markets. The products included caffeine, duloxetine hydrochloride, mebeverine hydrochloride, phenylephrine hydrochloride, trimebutine maleate and oxyclozanide, under licences valid until 28 May 2028. Deccan Remedies also received a three-year test licence for ranolazine, cinnarizine, sacubitril and triclabendazole, which was restricted to examination, testing or analysis rather than commercial sale. The subsidiary generated revenue of ₹52.99 crore and PAT of ₹4.85 crore in FY26, while Gennex’s consolidated FY26 operating revenue was about ₹173 crore.
Powered by Tijori
Premier Fiscal Services Pvt Ltd, the promoter of Gennex Laboratories, has pledged 2.5 million shares to Vidya Tradecon Pvt Ltd for a business loan of ₹1.25 crore. The pledge was created on June 9, 2026, and expires on December 7, 2026. This brings the total promoter pledged shares to 12.5 million, or 23.57% of the promoter's holding of 53 million shares. The promoter group's overall stake in the company stands at 21.83% of the total equity. The shares were valued at ₹2.5 crore at the time of the pledge, providing a cover ratio of two times the loan amount. The company's stock closed at approximately ₹10 per share on the BSE.
Powered by Tijori
Premier Fiscal Services Pvt Ltd, the promoter of Gennex Laboratories, has pledged 2.5 million shares to Vidya Tradecon Pvt Ltd for a business loan of ₹1.25 crore. The pledge was created on June 9, 2026, and expires on December 7, 2026. This brings the total promoter pledged shares to 12.5 million, or 23.57% of the promoter's holding of 53 million shares. The promoter group's overall stake in the company stands at 21.83% of the total equity. The shares were valued at ₹2.5 crore at the time of the pledge, providing a cover ratio of two times the loan amount. The company's stock closed at approximately ₹10 per share on the BSE.
Powered by Tijori
Oct 28 (Reuters) - Gennex Laboratories Ltd GNXL.BO:
UNIT GOT ANDHRA PRADESH GOVERNMENT APPROVAL TO MANUFACTURE ADDITIONAL PRODUCTS
Source text: ID:nBSE5F4rKr
Further company coverage: GNXL.BO
Oct 28 (Reuters) - Gennex Laboratories Ltd GNXL.BO:
UNIT GOT ANDHRA PRADESH GOVERNMENT APPROVAL TO MANUFACTURE ADDITIONAL PRODUCTS
Source text: ID:nBSE5F4rKr
Further company coverage: GNXL.BO
Nov 29 (Reuters) - Gennex Laboratories Ltd GNXL.BO:
TO CONSIDER FUNDRAISING BY WAY OF PREFERENTIAL ISSUE
Source text for Eikon: ID:nBSE4ndZ58
Further company coverage: GNXL.BO
Nov 29 (Reuters) - Gennex Laboratories Ltd GNXL.BO:
TO CONSIDER FUNDRAISING BY WAY OF PREFERENTIAL ISSUE
Source text for Eikon: ID:nBSE4ndZ58
Further company coverage: GNXL.BO
Nov 20 (Reuters) - Gennex Laboratories Ltd GNXL.BO:
TO CONSIDER PREFERENTIAL ISSUE OF SHARES TO SPECIFIC INDIVIDUALS AND ENTITIES
Source text for Eikon: ID:nBSEc4W2wz
Further company coverage: GNXL.BO
Nov 20 (Reuters) - Gennex Laboratories Ltd GNXL.BO:
TO CONSIDER PREFERENTIAL ISSUE OF SHARES TO SPECIFIC INDIVIDUALS AND ENTITIES
Source text for Eikon: ID:nBSEc4W2wz
Further company coverage: GNXL.BO
June 1 (Reuters) - Gennex Laboratories Ltd GNXL.BO:
UNIT RECEIVED LICENSE TO MANUFACTURE FOR SALE OF DRUGS FROM GOV OF ANDHRA PRADESH
Source text for Eikon: ID:nBSE4By8Zr
Further company coverage: GNXL.BO
June 1 (Reuters) - Gennex Laboratories Ltd GNXL.BO:
UNIT RECEIVED LICENSE TO MANUFACTURE FOR SALE OF DRUGS FROM GOV OF ANDHRA PRADESH
Source text for Eikon: ID:nBSE4By8Zr
Further company coverage: GNXL.BO
May 31 (Reuters) - Gennex Laboratories Ltd GNXL.BO:
UNIT GOT CFO APPROVAL FROM POLLUTION CONTROL BOARD
Source text for Eikon: ID:nBSE5JbWx6
Further company coverage: GNXL.BO
May 31 (Reuters) - Gennex Laboratories Ltd GNXL.BO:
UNIT GOT CFO APPROVAL FROM POLLUTION CONTROL BOARD
Source text for Eikon: ID:nBSE5JbWx6
Further company coverage: GNXL.BO
| Jun 26(Cr.) | YoY Change | QoQ Change | |
|---|---|---|---|
| Sales | 39.84 | 16.57% | -34.64% |
| Operating Profit | 4.38 | -13.74% | -25.65% |
| Net profit | 4.67 | -6.98% | 4.64% |
| Type | Jun 26 | Sep 26 | YoY Change | QoQ Change |
|---|---|---|---|---|
| Promoter | 23.63% | 23.63% | 0.01% | -- |
| Pledge | 21.77% | 21.77% | 4.34% | -- |
| FII | -- | -- | -- | -- |
| DII | -- | -- | -- | -- |
| Retail < 2L | 41.45% | 41.13% | -3.2% | -0.32% |
| Others | 34.92% | 35.24% | -- | 0.32% |
| No. of Shareholders | 82,886 | 81,481 | -9.79% | -1.7% |
| Name | M.CAP (Cr.) | PE | ROCE (%) | D/E |
|---|---|---|---|---|
| GENNEX | 219 | 11.27 | 10.15 | 0.36 |
| BROOKS | 188 | 14.26 | 5.26 | 0.06 |
| ACHYUT | 187 | 740 | 1.14 | -- |
| CORALAB | 178 | 9.26 | 10.77 | 0.02 |